Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PAFSC 1st Committee to Review Liovel, Nexium
April 25, 2011
- FJPWA May Have to Consider Rotational Operations: FJPWA President Bessho
April 25, 2011
- Korosho Draws up GL for R&D Use of Donated Blood
April 25, 2011
- No Remarkable Increases in Infections in Disaster-hit Areas: NIID
April 25, 2011
- Japan Should Join PIC/S to Harmonize Its GMP with Global Standards: Dr Sakurai of PMDA
April 25, 2011
- Teijin Pharma Announces New Global Partners for TMX-67
April 25, 2011
- DSP's Pharmacist Employees Volunteer to Assist in Disaster Area
April 25, 2011
- Nomura Securities Predicts Plummeting Profitability for Daiichi Sankyo's Pravastatin
April 25, 2011
- PMDA to Provide Consultation Services for Wider Range of OTC Drugs
April 25, 2011
- Yakult Licenses Resminostat from 4SC of Germany
April 25, 2011
- Korosho Publishes Medical Societies' Views on Switch OTC Drug Candidates
April 25, 2011
- Gov't to Enforce 25% Power Cuts This Summer for Major Users Including Drug Makers
April 18, 2011
- Gov't Appeals to High Court in Iressa Case
April 18, 2011
- Taisho Acquires Hoepharma of Malaysia
April 18, 2011
- Korosho Calls on Industry to Come Up with Energy Conservation Plans
April 18, 2011
- FDA Approves 1st New Treatment for Late-stage Melanoma in Over a Decade: BMS
April 18, 2011
- Eiken Licenses LAMP Technology to OptiGene
April 18, 2011
- ASKA Begins Shipments of Thyradin Substitute
April 18, 2011
- Review Period for QAB149 for COPD Extended 3 Months by FDA
April 18, 2011
- MCM Negotiates Partnership with Clearstone of Canada in CLS Services
April 18, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…